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Abstract Calpains, the thiol proteinases of the calcium-
dependent proteolytic system, are regulated by a natural 
inhibitor, calpastatin, which is present in brain tissue in two 
forms. Although both calpastatins are highly active on human 
erythrocyte calpain, only one form shows a high inhibitory 
efficiency with both rat brain calpain isozymes. The second 
calpastatin form is almost completely inactive against homol-
ogous proteinases and can be converted into an active one by 
exposure to a phosphoprotein phosphatase, also isolated from rat 
brain. Phosphorylation of the active calpastatin by protein kinase 
C and protein kinase A promotes a decrease in its inhibitory 
efficiency. The interconversion between the two inhibitor forms 
seems involved in the adjustment of the level of intracellular 
calpastatin activity on specific cell requirements. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
All mammalian cells contain a Ca2+-dependent proteolytic 
system, composed by one or more soluble thiol proteinase 
isoforms, named calpains, and by a specific calpain inhibitor, 
calpastatin [1-7]. Two calpain isozymes (u,-calpain and m-cal-
pain) are well known forms identified in many cells and tis-
sues, such as muscle, liver, kidney and brain [1—4,6]. Recently, 
the concept of a tissue-specific calpain form has also emerged 
[8], arising from the discovery of a 93 kDa calpain isozyme, 
exclusively localised in muscle cells. This proteinase form, 
however, was not well characterised, due to its very short 
life, also in transfected cells [7,8]. A function for this protein-
ase form in muscle cells is suggested by the correlation ob-
served between the lack of its expression and a type of mus-
cular dystrophy [9]. 
Regulation of calpain activity in the cells is accomplished 
by two factors; the first one is the [Ca2+], which must be 
increased, and the second one is due to the presence of cal-
pastatin which controls translocation of calpain to plasma 
membrane and thereby the activation process of the protein-
ase [1-3,7]. 
The composition of rat brain Ca2+-dependent proteolytic 
system is similar to that of the other tissues [4,10-14], con-
taining both classical ^.-calpain and wi-calpain and their inhib-
*Corresponding author. Fax. (39) 10-354415 
Abbreviations: PKA, cAMP-dependent protein kinase; PKC, Ca2+-
phospholipid-dependent protein kinase 
itor, calpastatin. The functions of calpains in brain cells are 
particularly relevant on vesicle secretion at synaptic termina-
tions and on long-term potentiation by degradation of cyto-
skeletal and neurofilament proteins, including calspectin, a 
spectrin-like molecule [10,12,14]. 
A number of laboratories are collecting evidences support-
ing the idea that calpains are involved in the aspecific degra-
dation of intracellular proteins and structures and brain seems 
particularly susceptible to this proteolysis [for a review, see 
[15]]. From the digestion patterns obtained in a variety of 
experimental conditions, it has been postulated that calpain-
induced cell damages can occur also in some pathological 
conditions [16-21] and particularly in postischemic tissues 
[10,12,14,22-25]. This hypothesis is further supported by the 
protective effects shown in vitro conditions by synthetic pro-
teinase inhibitors [22,23]. 
Due to the fact that the Ca2+-dependent proteolytic system 
also contains regulatory proteins, such as calpastatin and a 
calpain activator protein [3,26], expression of intracellular cat-
alytic activity by these proteinases must take in account the 
level and the efficiency of these accessory proteins. 
In this paper we studied the mechanism of regulation of this 
system in brain cells and identified two calpastatin forms with 
different inhibitory efficiency. The two forms are produced by 
phosphorylation-dephosphorylation process of a single pro-
tein. In addition, rat brain active calpastatin is very sensitive 
to degradation by wi-calpain. Alteration of these processes 
could be responsible for the modification of the regulatory 
system, promoting abnormal intracellular activation of cal-
pain. 
2. Materials and methods 
2.1. Materials 
Human erythrocyte calpain was purified to homogeneity as previ-
ously described [28]. Histone III S, phosphatidylserine, HEPES and 
dioleylglycerol were purchased from Sigma Chemical Co. (USA), 
[y-32P]ATP from Amersham, UK. 
2.2. Purification of calpains from rat brain 
Freshly collected brains from five rats (10 g) were suspended in 
5 volumes of 0.25 M sucrose containing 1 mM EGTA and 0.5 mM 
P-mercaptoethanol and disrupted by using a Potter Elvehjem homoge-
nizer. Cells were lysed by sonication (4 bursts of 10 s each) and the 
particulate material was discarded by centrifugation at lOOOOOXg for 
20 min. The clear supernatant (homogenate) was collected and loaded 
onto a DE-53 column (10 ml) equilibrated in 50 mM sodium acetate 
buffer, pH 6.7, containing 0.1 mM EGTA and 0.5 mM P-mercapto-
ethanol (Buffer A). The absorbed proteins were eluted by a salt gra-
dient from 0 to 0.35 M NaCl. The peaks containing calpain activities 
were separately collected, concentrated, dialyzed against 50 mM so-
dium borate buffer, pH 7.5, containing 0.1 mM EGTA, 0.5 mM 
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(3-mercaptoethanol (Buffer B) and 0.3 M NaCl, and loaded onto a 
Phenyl Sepharose CL 4B column (1X10 cm) equilibrated in the same 
dialysis buffer. This hydrophobic chromatography is crucial to remove 
any residual calpastatin activity which is not retained by the resin. 
The fractions containing the calpain activity were concentrated 
by ultrafiltration and loaded onto a Sephadex G-200 column 
(2X 120 cm) equilibrated in Buffer B. 
2.3. Purification of calpains from rat skeletal muscle 
it-Calpain and m-calpain were purified from rat skeletal muscle 
following the procedure described in [27]. 
2.4. Purification of calpastatins from rat brain 
Rat brain homogenates were prepared as described for calpains 
purification, then heated at 90°C for 3 min. The separation of the 
calpastatin forms has been achieved setting a very reproducible pro-
cedure using a 5-ml column packed with DE-cellulose, equilibrated in 
Buffer A, in a BioRad FPLC system. The absorbed proteins were 
eluted with a linear gradient of NaCl from 0 to 0.35 M, then 0.6 M 
NaCl was applied. Calpastatins were further purified following the 
procedure previously described for skeletal muscle calpastatins [27]. 
2.5. Assay of fl-calpain, m-calpain and calpastatin activities 
Calpains were routinely assayed as previously reported [27]. One 
unit of enzyme activity is the amount that releases 1 umol/h of free 
oc-amino groups under the specified assay conditions using acid-dena-
turated bovin globin as substrate. 
Calpastatin activity was routinely assayed as reported in [27] using 
human erythrocyte calpain, which has been shown to be the calpain 
isoform most sensitive to calpastatin inhibition. 
2.6. Purification of brain phosphatase 
Rat brain homogenates were prepared in Buffer A containing 50 |ig/ 
ml leupeptin and 1 mM phenylmethylsulfonyl fluoride, as described 
for calpains purification. The suspensions were centrifuged and ap-
plied on a DE-52 column (1 X 10 cm) equilibrated in the same buffer. 
The absorbed proteins were eluted by a salt gradient from 0 to 0.4 M 
NaCl. The fractions containing phosphatase activity were collected, 
concentrated to 2 ml by ultrafiltration and loaded on a Sephadex 
G200 column previously equilibrated in 50 mM sodium borate, pH 
7.5, containing 0.1 mM EDTA. The eluted fractions containing the 
phosphatase activity were collected and used. The procedure resulted 
in a purification of approximately 1150 fold. 
2.7. Preparation of [32P]histone 
Histone III S (1 mg) was incubated in 1 ml of sodium borate, pH 
7.5, containing 10 uM [32P]ATP (5X107 counts/min), 5 mM MgCl2, 
50 |xg of phosphatidylserine, 1 ug dioleylglycerol and 50 U of purified 
PKC. The mixture was incubated at 30°C for 30 min and loaded on a 
Sephadex G100 (2x 100 cm) previously equilibrated with 50 mM so-
dium borate, pH 7.5, containing 0.1 mM EDTA. The fractions con-
taining [32P]histone were collected, concentrated to 1 ml and the re-
sulting solution used as source of labelled histone (107 counts/min/ 
mg). 
2.8. Assay of phosphoprotein phosphatase 
The enzyme was assayed using [32P]histone as substrate by the 
procedure described in [29] and modified as follows. The mixture 
contained, in a final volume of 0.25 ml of 50 mM sodium acetate, 
pH 6.0, [32P]histone III S (50000 counts/min) and the appropriate 
amount of enzyme. One unit of phosphatase activity was defined as 
the amount causing the release of 1 nmol of phosphate groups from 
[32P]histone in 30 min at 37°C, in the specified conditions. 
2.9. Isolation of rat brain PKA and PKC 
Rat brains (10 g) were homogenized in 4 volumes of 10 mM 
HEPES, pH 7.5, containing 0.25 M sucrose, 0.5 mM EDTA and 
10 mM (i-mercaptoethanol. The soluble fraction was recovered fol-
lowing centrifugation at lOOOOOXg for 15 min and submitted to ion 
exchange chromatography on DE-cellulose as previously reported 
[30]. The eluted fractions were assayed for PKA and for PKC activity 
[30]. The fractions containing PKA (52-73) or PKC activity (79-137) 
were pooled and submitted to affinity chromatography on threonine-
Sepharose, as described in [31]. The fractions containing the protein 
kinase activities were collected, concentrated to 2 ml and then loaded 
onto a Sephadex G200 column (1.2 X 12 cm) equilibrated in 50 mM 
sodium borate, pH 7.5, containing 0.1 mM EDTA. The fractions 
containing protein kinase activities were pooled, concentrated and 
used as source of PKA or of PKC. One unit of protein-kinase activity 
was defined as the amount causing the incorporation of 1 nmol of 32P 
into histone type III S, in the conditions specified in [30]. 
3. Results 
3.1. Separation of calpastatin from rat brain 
Rat brain extracts were submitted to ion exchange chroma-
tography, in mild acid conditions, using a 5 ml column, con-
taining DE-53 resin. The eluted calpastatin activity was as-
sayed using human erythrocyte calpain, previously shown to 
be very sensitive to inhibition by calpastatin, independently 
from the source of the inhibitor. As shown in Fig. 1A, calpa-
statin activity, present in rat brain extracts, was fractionated 
in two distinct peaks, the first one emerging at approximately 
0.09-0.1 M NaCl and the second one at 0.2 M NaCl. The 
presence of two peaks almost equally represented was not due 
to the concomitant elution of calpain; in fact, the same pat-
tern has been obtained with homogenates previously heated at 
90° for 3 min, a treatment which completely inactivated cal-
pain activity (data not shown). The fractions containing the 
two peaks of inhibitory activity, named calpastatin I and II, 
respectively, were separately collected and these proteins were 
further purified, accordingly to the procedure described in 
Section 2. In all these steps, calpastatin activity was routinely 
assayed using the human erythrocyte calpain. 
3.2. Inhibitory efficiency of rat brain calpastatins 
The efficiency of the two calpastatin forms was then tested 
on a- and m-calpain, also purified from rat brain (Fig. 1B,C). 
Calpastatin I inhibited both calpain isoforms (Fig. IB), show-
ing a slightly higher efficiency for the (a.-isozyme. Calpastatin 
II, however, expressed very poor inhibitory activity against 
both brain proteinases (Fig. 1C), although it was able to in-
hibit the human erythrocyte calpain, with an efficiency com-
parable to that of calpastatin I. To verify that these differ-
ences in activity between the calpastatin I and II are not due 
to artifacts of the experimental procedures, the two inhibitors 
were also tested on \i- and m-calpain purified from rat skeletal 
muscle [27]. The results obtained were very similar to those 
shown in Fig. 1B,C (data not shown), indicating that calpa-
statin II is a low active protein inhibitor probably representing 
a reservoir to be utilized in specific cell conditions. 
3.3. Effect of a rat brain phosphoprotein phosphatase on the 
properties of rat brain calpastatins 
This hypothesis implies the possibility that calpastatin II 
might be converted in an active form, similar to calpastatin 
I. This idea is supported by the evidence that, by exposing 
calpastatin II to the action of a phosphoprotein phosphatase 
also isolated from rat brain, the chromatographic properties 
of this inhibitor form were modified (Fig. 2A), becoming sim-
ilar to that of calpastatin I. In parallel, following the treat-
ment with the phosphatase, a large increase in inhibitory effi-
ciency has been observed (Fig. 2B). With this procedure, 
calpastatin II has been converted into a form showing molec-
ular and functional properties similar to those of calpastatin I. 
Exposure of calpastatin I to the same treatment had no effect 
on its molecular or inhibitory properties (data not shown). 
Taken together, these data suggest the existence of an inter-
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Fig. 1. Properties of the two calpastatin forms from rat brain. A: Rat brain homogenate was fractionated by ion-exchange chromatography, as 
described in Section 2. The absorbed proteins were eluted with a linear gradient of NaCl from 0 to 0.35 M, and then the column was washed 
with the same buffer containing 0.6 M NaCl. The eluted fractions were assayed for calpastatin activity using human erythrocytes calpain, in 
the conditions specified in Section 2. B,C: The separated calpastatin I and II forms were further purified, as described in Section 2. Rat brain 
u,-calpain (O). and m-calpain (•) were then assayed in the presence of the indicated amounts of purified calpastatin I or calpastatin II (see Sec-
tion 2). The results are expressed as percentage of the calpain activity measured in the absence of any inhibitor. For comparison, inhibition of 
human erythrocyte calpain by the two calpastatins, determined in the same conditions, is also shown (□). 
conversion process between the two calpastatins, promoted by 
a dephosphorylation-phosphorylation process. 
3.4. Phosphorylation of rat brain calpastatin I 
To establish if calpastatin I could be phosphorylated, we 
have isolated the two major rat brain protein kinases, PKA 
and PKC. Calpastatin I was then incubated with these puri-
fied kinases for 30 min and the mixtures were submitted to a 
SDS-PAGE. At the end of the electrophoretic runs, SDS was 
removed and the gels were then cut in 2 mm slices. Each slice 
was collected and the proteins were eluted in 50 mM borate 
buffer, pH 7.5, containing 0.1 mM EDTA, following mechan-
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Fig. 2. Change in properties of calpastatin II following treatment with brain phosphoprotein phosphatase. A: Calpastatin II was isolated from 
rat brain as described in Section 2 and in the legend to Fig. 1A. The phosphoprotein phosphatase was purified from rat brain following the 
procedure described in Section 2. Calpastatin II was incubated with rat brain phosphoprotein phosphatase in sodium acetate buffer, pH 6.0, at 
37°C for 30 min, then the reaction was stopped by heating at 90°C for 3 min. The solution was submitted to DE-53 chromatography in the 
same conditions used in Fig. 1A. The elution profile of untreated calpastatin II (•) and that of phosphatase-treated calpastatin II (o) are 
shown. B: The inhibitory efficiency of untreated calpastatin II (•) and of phosphatase-treated calpastatin II (o) were assayed using purified rat 
brain m-calpain, in the conditions specified in Section 2. 
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Fig. 3. Phosphorylation of calpastatin I with PKA or PKC. Calpastatin I was incubated with purified PKA in the presence of cAMP and 
[732P]ATP (A) or with PKC in the presence of phospholipids and diacylglycerol (B), as described in Section 2. To the incubations, the same 
volume of a solution containing 4% SDS and 10 mM p-mercaptoethanol (final concentrations) was added, and the mixtures heated at 100°C 
and submitted to SDS-PAGE. At the end of the electrophoretic run, the gel was removed, washed with 50 mM borate buffer, pH 7.5, contain-
ing 20% methanol and 5 mM P-mercaptoethanol and cut in 2 mm slices. The protein present in each slice was eluted as described in Section 2 
and the resulting solutions were divided in two aliquots; the first one was used for the determination of the radioactivity content (•) and the 
second one for the measurements of the inhibitory capacity on human erythrocyte calpain activity (▲). As control, protein kinases were incu-
bated as above without calpastatin and the mixtures were submitted to SDS-PAGE. The gels were cut in 2 mm slices and the radioactivity was 
determined (o). C: Calpastatin I was incubated with purified PKC (•) or PKA (o) as above and, at the times indicated, aliquots of the incu-
bation mixtures were collected, heated at 90°C for 2 min to inactivate the kinases and centrifuged at 50000xg. To the clear solutions, Ca2+ 
ions were added to a final concentration of 1 mM and the mixtures loaded onto 1-ml column filled with Sepharose-immobilized carboxyme-
thyled human erythrocyte calpain [27] and equilibrated with 50 mM sodium borate buffer, pH 7.5, containing 1 mM Ca2+. The column was 
washed with 3-column-volume of the same buffer and the retained calpastatin was eluted substituting in the buffer the Ca2+ ions with 1 mM 
EDTA. The eluted protein, the calpastatin activity and the associated radioactivity were determined as described in Section 2. The incorpora-
tion of phosphate groups into calpastatin was expressed as mol of 32P per mol of inhibitor. 
ical disruption of the gel samples. The clear solutions were 
collected and divided into two aliquots; the first one was 
counted, and the second one was used to assay calpastatin 
activity. As shown in Fig. 3A, under the peak of calpastatin 
activity, a peak of radioactivity was also detected, indicating 
that calpastatin I was phosphorylated. Both PKC (Fig. 3A) 
and PKA (Fig. 3B) are capable to phosphorylate calpastatin 
in in vitro conditions. Incubation of calpastatin with PKC 
promotes the incorporation of 1.2-1.3 equivalents of 32P per 
calpastatin molecule; exposure to PKA induces the incorpo-
ration of 0.75-0.8 equivalents of 32P per calpastatin molecule 
(Fig. 3C). 
Taken together, these results confirm that phosphorylation 
and dephosphorylation of calpastatin can occur in cell-free 
system; the different incorporation of phosphate groups, ob-
served with PKA and PKC, can be explained on the basis of 
different accessibility of the phosphorylable sites. 
3.5. Degradation of brain calpastatin I by homologous calpain 
To obtain an abnormal intracellular activation of calpain, a 
modification of the mechanism of regulation must occur. Due 
to the fact that, following the formation of the calpain-cal-
pastatin complex, the inhibitor can be slowly degraded [32], 
prolonged activation of the proteinase may result in extensive 
digestion of this regulatory component. To verify the suscep-
tibility of brain calpastatin I to degradation by homologous 
calpain, we promoted the formation of the enzyme-inhibitor 
complexes and we measured the possible disappearance of 
calpastatin activity. As shown in Fig. 4, calpastatin I was 
almost completely resistant to |x-calpain, whereas it was very 
quickly inactivated by w-calpain. To better characterize this 
process, we tested calpains isolated from rat skeletal muscle. 
Also when incubated with the proteinases from this tissue, 
calpastatin I resulted preferentially degraded by m-calpain, 
although with less efficiency, as compared with the same iso-
zyme from brain (Fig. 4). 
The high susceptibility of calpastatin to degradation by ho-
mologous m-calpain and the interconversion between the two 
calpastatin forms may represent the basis for the production 
of cellular conditions suitable for uncontrolled activation of 
calpain. 
4. Discussion 
Many reports are suggesting that brain intracellular struc-
tures are particularly susceptible to calpain degradation, [15-
25,33-35]. To produce these effects, calpain must escape to a 
complex mechanism of modulation, which the evolution has 
developed around the proteinase. In fact, the first level of 
regulation is intrinsic to calpain molecules, which contain in-
tramolecular constraints capable to prevent the expression of 
catalytic activity [28], modulating the accessibility of the active 
site and stabilizing inactive conformations. The second level is 
represented by the natural inhibitor, which controls the num-
F. Salamino et al.lFEBS Letters 412 (1997) 433-438 437 
100 
K 
u 
(0 
I 
Acknowledgements: This work was supported in part by grants from 
the National Research Council (CNR), MURST and by Associazione 
Italiana per la Ricerca sul Cancro. 
References 
50 
Time, min 
100 
Fig. 4. Degradation of calpastatin I by calpains. Calpastatin I (7 
units) was incubated with the same units of rat brain m-calpain (•), 
rat brain u-calpain ( ♦ ) , rat skeletal muscle m-calpain (O) or rat 
skeletal muscle u,-calpain ( 0 ) in 0.7 ml of 50 mM sodium borate 
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of u- or m-calpain, respectively. Rat skeletal muscle calpains were 
purified following the procedure described in [27]. At the times indi-
cated, aliquots of the incubation mixtures (corresponding to 0.5 cal-
pastatin units) were collected, heated to 90°C for 2 min to inactivate 
the proteinases and centrifuged at 50000Xg for 10 min. The clear 
solutions were collected and assayed for their content of calpastatin 
activity. The results are expressed as percentage of calpastatin activ-
ity recovered following the same treatments, without exposure to 
proteinases. 
ber of the calpain molecules that must be activated, as well as 
the expression of catalytic activity [5,36]. 
In this paper, we are providing evidence on the molecular 
bases through which the Ca 2 + -dependent proteolytic system 
can be involved in aspecific degradation of brain cell struc-
tures. Using a very sensitive calpain form, we have demon-
strated that rat brain contains, in addition to the well-known 
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observed also in other rat tissues where the process has been 
considered as a tool required to change the selectivity of cal-
pastatin for one or the other calpain form [27,37]. In brain, 
however, this process could be visualised as the mechanism 
that fits the actual inhibitory activity to the cell requirement. 
The high sensitivity of calpastatin to degradation by w-cal-
pain, and particularly by the homologous proteinase, seems a 
peculiar property of brain tissue. The loss of this regulatory 
component of the system, together with the interconversion 
process, might produce further and uncontrolled activation of 
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